



Review on Various Biological Activities of Curcumin

Baravkar M.C.¹, Durunde N.R.,²

Department of Pharmaceutical Chemistry, School of Pharmacy & Research Centre, Shardanagar, Baramati, Pune-412208.
manjushanevase@gmail.com

Abstract


Curcumin, a yellow substance belonging to the polyphenols super family, is the active component of turmeric, a common Indian spice, which is derived from the dried rhizome of the *Curcuma longa* plant. Numerous studies have demonstrated that curcumin possesses anti-oxidant, anti-inflammatory and anticancerous properties. The purpose of this review is to focus on the anti-tumor effects of curcumin. Curcumin inhibits the STAT3 and NF- κ B signaling pathways, which play key-roles in cancer development and progression. Also, inhibition of Sp-1 and its housekeeping gene expressions may serve as an important hypothesis to prevent cancer formation, migration, and invasion. Recent data have suggested that curcumin may act by suppressing the Sp-1 activation and its downstream genes, including ADEM10, calmodulin, EPHB2, HDAC4, and SEPP1 in a concentration- dependent manner in colorectal cancer cell lines; these results are consistent with other studies, which have reported that curcumin could suppress the Sp. Clinical trials of curcumin have been completed or are ongoing for various types of cancer. This review presents the molecular mechanisms of curcumin in different types of cancer and the evidence from the most recent clinical trials.

Keywords: Curcumin, Cancer, Cell signaling pathways

Introduction

Curcuma longa, commonly known as turmeric, is a herbaceous plant belonging to the ginger family.¹ The plant produces a variety of secondary metabolites including flavonoids, alkaloids, tannins and phenolic acids², among which the active hydrophobic polyphenol diferuloyl methane, named curcumin, is of special notice³. Curcumin is used in the treatment of various health conditions, including inflammatory disorders, liver disease, metabolic syndrome, neurodegenerative diseases and, most importantly, in several types of cancer. The chemical structure of curcumin, as well as the most important

curcuminoids, namely demethoxy curcumin and bis-demethoxy curcumin, is presented in Figures, Given below



Cancer is among the primary causes of death worldwide and, despite the high-level of global awareness and the development of multitargeted therapeutic options, death rates from cancer are still

significantly high². Cancer cells are characterized by disruption of several signaling pathways including those responsible for angiogenesis, proliferation, metabolism, migration,

Immune modulation and survival³. Curcumin has been found to affect cancer cells in a variety of ways leading to the prevention of cancer formation. Its

most prominent effects on cancer are summarized in Figure 2.




Figure No. 2 : Summarized effects of curcumin on cancer cells

Key: CDK2, cyclin-dependent kinase 2; MMP-2, matrix metalloproteinase 2; MMP-9, matrix metalloproteinase 9; VEGF, vascular endothelial growth factor; NF-kB, nuclear factor kappa-light-chain-enhancer of activated B cells, mTOR, mechanistic target of rapamycin; PTEN, phosphatase and tensin homolog; bcl-2, B-cell lymphoma-2; bax, Bcl-2-associated X protein.

Curcumin has shown promising results in the treatment of several types of cancer both alone and in combination with other antineoplastic agents. It affects several signaling pathways and can thus effectively modify both the development and the growth of various tumors.⁴ This review summarizes the immunomodulatory effects of curcumin and the most recent evidence on the effectiveness of the growth of tumors⁵ Curcumin acts on the regulation of different immune modulators, resulting in some of its anticancer properties. ROS are molecules derived from oxygen with the ability to act as secondary messengers in several cellular signaling pathways. They participate in inflammation and in

curcumin in the treatment of different types of cancer in vitro both alone and in combination with other chemotherapeutic agents.⁶

2. Immunomodulatory Effects of Curcumin⁷

Chronic inflammation disorders and infectious diseases are responsible for the development of several types of cancer, contributing to genomic instability, which is considered a hallmark of cancer. The inflammatory process results in the production of several pro-inflammatory molecules, including reactive oxygen species (ROS), nuclear factor kappa-light-chain-enhancer of activated B cells (NF-Kb), cytokines, AKT, the transcription factor activator protein-1 (AP-1), and cyclooxygenase-2 (COX-2), which are involved in both the initiation and cell survival, differentiation and proliferation, resulting in the progress of different types of cancer¹¹. Curcumin binds directly to ROS scavengers and may thus suppress the growth and metastasis of some types of cancer¹².




Figure No. 3 :-Immunomodulatory Effects of Curcumin¹³


Anticancer properties of curcumin

Curcumin has long been used as a dietary ingredient with known health benefits. Extensive research over the last decade has shown that curcumin possesses anticancer activities and could be used as a preventive or treatment agent against cancers, either as a single or combination therapy with chemotherapeutic agents.¹⁴ Curcumin exhibits biological activities in various stages of carcinogenesis including inhibition of oncogenic activation, prevention of cancer-related inflammation, inhibition of cancer cell proliferation, induction of apoptosis and anionic, prevention of metastasis and sensitization of cancer cells to chemotherapy.¹⁵

Cancer Prevention

Cancer is multistep process driven by genetic instability. Continuous exposure to environment and endogenous genotoxic agents can cause substantial DNA damage. The damage molecule can be transmitted during cell division producing mutated clones that can give rise to the expansion of premalignant cell population possessing uncontrolled proliferative and invasive properties. Curcumin has been established as a chemo preventive agent that has the ability to suppress or retard the carcinogenic

process induced by various chemical carcinogens¹⁶. In animal models of gastric and colon cancer curcumin inhibits the development of cancerous and precancerous lesions induced by N-methyl-N'-nitro-N-nitrosoguanosine (MNNG), a known mutagenic agent causing DNA methylation. In the study, MNNG was given in drinking water at the concentration of 100 ppm for 8 weeks, and then 0.2% or 0.5% of curcumin was fed to the rats for 55 weeks. The results showed that the number of atypical hyperplasia in curcumin-treated rats was significantly less than that in the control group. Similarly, the curcumin analog bis-1,7-(2-hydroxyphenyl)-hepta-1,6-diene-3,5-dione was shown to inhibit the tumorigenic effect of 1,2-dimethylhydrazine in rats (Devasena et al., 2003). Furthermore, natural and synthetic curcuminoids exhibit an inhibitory effect on mutagenesis induced by 2-acetamidofluorene (2-AAF) (Anto et al., 1996).¹⁷ In the study, up to 87% of 2-AAF-induced papilloma was inhibited by bis-(p-hydroxy cinnamoyl)methane (curcuminoid III), while 70% and 68% of the papilloma were inhibited by feruloyl-phydroxy cinnamoyl methane (curcuminoid II) and diferuloylmethane (curcuminoid I), respectively. The most potent curcuminoid was salicyl curcuminoid which completely inhibited the papilloma formation.¹⁸




Anti-inflammatory activity

Epidemiological studies have supported the concept that cancers frequently originate at the site of chronic inflammation. This event has increasingly been accepted as the seventh hallmark of cancer. Inflammation is a vital physiological process in response to injury, which leads to the mediation of inflammatory cells in the presence of enzymes and cytokines for repairing tissue damage.¹⁹ The linkage between cancer and inflammation is generally characterized as being intrinsic or extrinsic. The extrinsic pathway is induced by inflammation that facilitates cancer development, while the intrinsic pathway is driven by genetic instability causing

inflammatory environment-related cancer.²⁰ Both processes mediate the transcription factors involved in cell proliferative function and persistent activation of this event can lead to cancer. A considerable number of reports have described the linkage between cancer preventive properties and anti-inflammatory action of curcumin. Mechanistically curcumin inhibits the induction of nitric oxide synthase (NOS) by activated macrophages.²¹

Anti-Cancer Activity: Suppression of Carcinogenesis



Curcumin has been studied in multiple human carcinomas including melanoma, head and neck, breast, colon, pancreatic, prostate and ovarian cancers^{22,23}. Epidemiological studies attribute the low incidence of colon cancer in India to the chemo preventive and antioxidant properties of diets rich in curcumin²⁴. The mechanisms by which curcumin exerts its anti-cancer effects are comprehensive and diverse, targeting many levels of regulation in the processes of cellular growth and apoptosis. Besides the vertical effects of curcumin on various transcription factors, oncogenic and signaling proteins, it also acts at various temporal stages of carcinogenesis from the initial insults leading to DNA mutations through the process of tumor genesis, growth and metastasis (Figure 2). Because of the far-reaching effects and multiple targets of curcumin on the cell growth regulatory processes, it holds much promise as a potential chemotherapeutic agent for many human cancers. Curcumin's potent

anti-oxidant and free-radical quenching properties play an important role in the inhibitory effects of the compound on the initial stages of carcinogenesis. It has been shown that curcumin has the ability to suppress UV irradiation-induced DNA mutagenesis and induction of cellular SOS functions²⁵. In addition to the inhibitory effects on the production of nitric oxide and the ability to scavenge DNA damaging superoxide radicals, curcumin also affects both the Phase I and Phase II enzymes of the hepatic Cytochrome p450 enzyme system involved in the oxidation and detoxification of toxic substances. Curcumin has been shown to inhibit the Phase I enzymes (including Cytochrome p450 isoforms and p450 reductase) which are induced in response to toxin exposure and create a host of carcinogenic metabolites that contribute to DNA adduct formation during the oxidation of such substances²⁶

Health Benefits of Curcumin³⁰



Figure No. 6: Health Benefits of Curcumin³¹

A model illustrating the multiple molecular targets of curcumin in various cancers

Anticancer Effects of Curcumin

Curcumin was used as a remedy in ancient Chinese and traditional Indian medicine for the treatment of various ailments. The medicinal application of curcumin has been in use since the Unani and the Vedic ages. Curcumin disrupts the signaling pathways and molecular targets involved in the initiation and progression of various cancers (Fig. 6). The following are the different forms of cancer for which curcumin has been shown to be an efficacious treatment. These results fuel the momentum of its clinical use in cancer management.

www.ijprt.com

pathways and molecular targets involved in the initiation and progression of various cancers (Fig. 6). The following are the different forms of cancer for which curcumin has been shown to be an efficacious treatment. These results fuel the momentum of its clinical use in cancer management.

Digestive System Cancers

1) Esophageal Cancer

Esophageal cancer arises in the tissues lining the esophagus, the muscular tube through which food passes from the throat to the stomach. In the United States, there will be an estimated 17,460 (13,950 men and 3,510 women) new cases resulting in 15,070 (12,040 men and 3,030 women) deaths from esophageal cancer in 2012³². Curcumin is considered a potential candidate for the treatment and prevention of esophageal cancer due to its inhibition of inflammatory markers such as NF- κ B. Curcumin not only inhibits NF- κ B but also increases the occurrence of apoptosis and the accumulation of drugs in the esophageal adenocarcinoma cells³³. Additionally, treatment with curcumin reversed the bile acid induction of COX-2 and suppression of gene expression associated with sodium dismutase-1 in the esophageal HET-1A epithelial cell lines³⁴. Curcumin modulates a variety of molecular targets and induces apoptosis-independent death by mechanisms such as autophagy in esophageal cancer cells³⁵. Recently, it has been reported that curcumin modulated Notch-1 signaling and inhibited NF- κ B and its downstream targets including Bcl2, cyclin D1, VEGF and MMP-9 in oral squamous cell carcinomas³⁶. Furthermore, curcumin abrogated the bile-induced NF- κ B activity and DNA damage, and promoted apoptosis, *in vivo*, as a result suggesting its chemopreventive use in the rat esophagus³⁷. It has been shown that curcumin fed to rats during the cancer initiation and post initiation stages repressed the occurrence of esophageal carcinogenesis by 27 and 33%, cancer initiation and post initiation stages repressed the occurrence of esophageal carcinogenesis by 27 and 33% respectively³⁸.

2) Gastric Cancer³⁹

Gastric cancer refers to a cancer that arises from any part of the stomach. According to the American Cancer Society survey, there will be an estimated 21,320 (13,020 men and 8,300 women) new cases and 10,540 (6,190 men and 4,350 women) deaths resulting from gastric cancer in the United States in 2012

3) Intestinal Cancer

Intestinal cancer arises in the small intestine, the organ which transports food from the stomach to the colon during the digestion process.³⁹

4) Hepatic Cancer:-

Hepatic cancer is also called hepatocellular carcinoma (HCC) or liver cancer, as the liver is the location where this cancer originates. In 2012, in the United States, a total of 28,720 (21,370 men and 7,350 women) new cases of hepatic cancer will have been diagnosed and 20,550 (13,980 men and 6,570 women) patients will die from this type of cancer.⁴⁰

5) Pancreatic Cancer

Pancreatic cancer is a major cause of cancer-related mortalities accounting for 6% of all cancer-related deaths in men and women. It is estimated that a total of 43,920 (22,090 men and 21,830 women) new cases and 37,390 (18,850 men and 18,540 women) deaths related to pancreatic cancer will occur in the United States in 2012⁴¹

Effect on Cell Cycle Regulation and Apoptosis

Cellular growth and proliferation is a highly regulated event in normal cells, and derangements of the cell cycle can lead to uncontrolled proliferation and contribute to the malignant phenotype of tumor cells. The mammalian cell cycle consists of four main stages: G₁, S, G₂ and M, with G₁ and G₂ being referred to as “gap” phases between the events of DNA synthesis and mitosis, respectively. In addition, there is a fifth phase, referred to as G₀ which represents a state of quiescence outside the cell cycle in which cells are not actively dividing or preparing to divide. Control of the cell cycle is accomplished via the coordinated interaction of cyclins with their respective cyclin-dependent kinases (CDKs) to form active complexes and drive cells into the next phase

at the appropriate time.⁴¹ Inactivation of Rb and p53 proteins occurs by phosphorylation for the progression of the cell cycle from the G1 to the S

phase. Kinase function of CDK4 is activated by cyclin D1 and inactivated by p16 proteins.




Figure No.7: Cell cycle regulation by Rb and p53 tumor suppressor proteins.

Conclusion

Cancer is not one disease but a combination of many; to effectively halt tumor progression, a drug that can target multiple dysregulated proteins would be ideal. Targeted therapies have their limitations, the most prominent being that cancer cells develop resistance to them. In some patients whose cancer develops resistance to imatinib, for example, a mutation in the BCR-ABL gene has changed the protein so, that it no longer can bind to this drug. In most such cases, another targeted therapy that could overcome this resistance is not available. Combinations of targeted therapies with either other targeted therapies or more traditional therapies may be the solution to this

References

1. Priyadarsini, K.I. *The chemistry of curcumin: From extraction to therapeutic agent.* *Molecules* 2014, 19, 20091–20112.
2. Dutta, B. *Study of secondary metabolite constituents and curcumin contents of six*

problem. Curcumin and its analogues have been demonstrated to possess various anticancer properties in a series of cancer cell lines, such as pancreatic, lung, ovarian, oral, colorectal, breast carcinoma and even in melanoma cells. In the future, further research will ascertain or not the potential of curcumin analogues as effective chemotherapy agents.

Acknowledgement

The authors are thankful to the staff of School of Pharmacy & Research Centre, Shardanagar, Baramati for support for the work.

different species of genus curcuma. *J. Med. Plants* 2015, 3, 116–119.

3. Kyritsis, A.; Bondy, M.; Levin, V. *Modulation of Glioma Risk and Progression by Dietary Nutrients and Antiinflammatory Agents.* *Nutr. Cancer* 2011, 63, 174-184.

4. Heling's, S.J.; Kalman, D.S. Curcumin: A Review of Its' Effects on Human Health. *Foods* 2017, 6, 92. [
5. World Health Organization. *Global Action against Cancer*; World Health Organization: Geneva, Switzerland, 2005.
6. Siegel, R.L.; Miller, K.D.; Jemal, A. *Cancer statistics, 2020*. *CA Cancer J. Clin.* 2020, 70, 7–30.
7. Pentimalli, F.; Grelli, S.; Daniele, N.; Melino, G.; Amelio, I. Cell death pathologies: Targeting death pathways and the immune system for cancer therapy. *Genes Immun.* 2019, 20, 539-554.
8. Murata, M. *Inflammation and cancer*. *Environ. Health Prev. Med.* 2018, 23, 50.
9. Negrini, S.; Gorgoulis, V.; Halazonetis, T. Genomic instability An evolving hallmark of cancer. *Nat. Rev. Mol. Cell Biol.* 2010, 11, 220-228.
10. Mohamed, S.I.A.; Jantan, I.; Haque, M.A. Naturally occurring immune modulators with antitumor activity: An insight on their mechanisms of action. *Int. Immuno pharmacol.* 2017, 50, 291-304.
11. Schieber, M.; Chandel, N.S. ROS function in redox signaling and oxidative stress. *Curr. Biol.* 2014, 24, 453–462.
12. Nakamae, I.; Morimoto, T.; Shima, H.; Shionyu, M.; Fujiki, H.; Yoneda-Kato, N.; Yokoyama, T.; Kanaya, S.; Kakiuchi, K.; Shirai, T.; et al. Curcumin Derivatives Verify the Essentiality of ROS Upregulation in Tumor Suppression. *Molecules* 2019, 24, 4067.
13. <https://www.vyomoverseas.com/health-benefits-of-turmeric-to-live-a-good-life/>
14. Diehl, J.A. (2002) Cycling to cancer with cyclin D1. *Cancer Biology & Therapy*, Vol. 1, No. 3, (May- June 2002), pp. 226-231, ISSN 1555-8576 .
15. Dorai, T., Gehani, N., & Katz, A. (2000). Therapeutic potential of curcumin in human prostate cancer. II. curcumin inhibits tyrosine kinase activity of epidermal growth factor receptor and depletes the protein. *Molecular Urology*, 4(1): 1-6.
16. Aggarwal, B.B., Shishodia, S., Takada, Y., Banerjee, S., Newman, R.A., Bueso-Ramos, C.E., and Price, J.E. Curcumin suppresses the paclitaxel-induced nuclear factor-kappa B pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. *Clinical Cancer Research*, 2005;11(20) : 7490-7498.
17. Amanda, M.G., & Robert, A.O. Curcumin and resveratrol inhibit nuclear factor-kappaB-mediated cytokine expression in adipocytes. *Nutrition and Metabolism*, 2008;12(5):1-13.
18. Anto, R.J., George, J., Babu, K.V., Rajasekharan, K.N., & Kuttan, R. (1996) Antimutagenic and anticarcinogenic activity of natural and synthetic curcuminoids. *Mutation Research*, 1996;370 (2)127-131.
19. Cheng, C.Y., Lin, Y.H., & Su, C.C. Curcumin inhibits the proliferation of human hepatocellular carcinoma J5 cells by inducing endoplasmic reticulum stress and mitochondrial dysfunction. *International Journal of Molecular Medicine*, 2010;26(5): 673-678.
20. Chignell, C.F., Bilski, P., Reszka, K.J., Motten, A.G., Sik, R.H., & Dahl, T.A. Spectral and photochemical properties of curcumin. *Photochemistry and Photobiology*, 1994;59 (3): 295-302.
21. Chiu, T.L., and Su, C.C. Curcumin inhibits proliferation and migration by increasing the Bax to Bcl-2 ratio and decreasing NF-kappaBp65 expression in breast cancer MDAMB-231 cells. *International Journal of Molecular Medicine*, 2009 ;23(4) :469-475.
22. Aggarwal S, Takada Y, Singh S, Myers JN, Aggarwal BB: Inhibition of growth and survival of human head and neck squamous cell carcinoma cells by curcumin via modulation of nuclear factor-kB signaling. *Int J Cancer* 2004, 111:679-692.
23. LoTempio MM, Veena MS, Steele HL, Ramamurthy B, Ramalingam TS, Cohen AN, Chakrabarti R, Srivatsan ES, Wang MB: Curcumin suppresses growth of head and neck squamous cell carcinoma. *Clin Cancer Res* 2005, 11:6994-7002.
24. Wang D, Veena MS, Stevenson K, Tang C, Ho B, Suh JD, Duarte VM, Faull KF, Mehta K, Srivatsan ES, Wang MB: Liposome-encapsulated curcumin suppresses growth of head and neck squamous cell carcinoma in vitro and in xenografts through the inhibition of nuclear factor kappa B by AKT-independent pathway. *Clin Cancer Res* 2008, 14:6228-6236.
25. Mukhopadhyay A, Bueso-Ramos C, Chatterjee D, Pantazis P, Aggarwal BB: Curcumin downregulates cell survival mechanisms in

- human prostate cancer cell lines. *Oncogene* 2001, 20:7597-7609.
26. Siwak DR, Shishodia S, Aggarwal BB, Kuzrock R: Curcumin-induce antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IkappaB kinase and nuclear factor kappaB activity and are independent of the B-Raf/mitogen-activated/extracellular signal-regulated protein kinase pathway and the Akt pathway. *Cancer* 2005, 104:879-890.
 27. Mohandas KM, Desai DC: Epidemiology of digestive tract cancers in India V. Large and small bowel. *Indian J Gastroenterol* 1999, 18:118-121.
 28. Oda Y: Inhibitory effect of curcumin on SOS functions induced by UV irradiation. *Mutat Res* 1995, 348:67-73.
 29. Thapliyal R, Maru GB: Inhibition of cytochrome p450 isoenzymes by curcumins in vitro and in vivo. *Food Chem Toxicology* 2001, 39:541-547.
 30. Siegel, R., Naishadham, D., and Jemal, A. (2012) *Cancer statistic. CA Cancer. J. Clin.* 62,1029.
 31. Hartojo, W., Silvers, A. L., Thomas, D. G., Seder, C. W., Lin, L., et al. (2010) Curcumin promotes apoptosis, increases chemosensitivity, and inhibits nuclear factor kappaB in esophageal adenocarcinoma. *Transl. Oncol.* 3, 99–108.
 32. Bower, M. R., Aiyer, H. S., Li, Y., and Martin, R. C. (2010) Chemoprotective effects of curcumin in esophageal epithelial cells exposed to bile acids. *World. J. Gastroenterol.* 16, 4152–4158
 33. O'Sullivan-Coyne, G., O'Sullivan, G. C., O'Donovan, T. R., Piwocka, K., and McKenna, S. L. (2009) Curcumin induces apoptosis-independent death in oesophageal cancer cells. *Br. J. Cancer.* 101, 1585–1595.
 34. Subramaniam, D., Pomeranian, S., Ramamoorthy, P., Standing, D., Battafarano, R. J., et al. (2012) Curcumin induces cell death in esophageal cancer cells through modulating Notch signaling. *PLoS One* 7, e30590.
 35. Schulze-Tanzil G, Mobasheri A, Sendzik J, John T, Shakibaei M: Effects of curcumin (diferuloylmethane) on nuclear factor kappa B signaling in interleukin-1beta-stimulated chondrocytes. *Ann N Y Acad Sci* 2004, 1030:578-586.
 36. LoTempio MM, Veena MS, Steele HL, Ramamurthy B, Ramalingam TS, Cohen AN, Chakrabarti R, Srivatsan ES, Wang MB: Curcumin suppresses growth of head and neck squamous cell carcinoma. *Clin Cancer Res* 2005, 11:6994-7002.
 37. Tomita M, Kawakami H, Uchihara JN, Okudaira T, Masuda M, Takasu N, Matsuda T, Ohta T, Tanaka Y, Ohshiro K, Mori N: Curcumin (diferuloylmethane) inhibits constitutive active NF-kappaB, leading to suppression of cell growth of human T-cell leukemia virus type Iinfected T-cell lines and primary adult T-cell leukemia cells. *Int J Cancer* 2006, 118:765-772.
 38. Rawat, N., Alhamdani, A., McAdam, E., Cronin, J., Eltahir, Z., et al. (2012) Curcumin abrogates bile-induced NF-jB activity and DNA damage in vitro and suppresses NF-jB activity whilst promoting apoptosis in vivo, suggesting chemopreventive potential in Barrett's oesophagus. *Clin. Transl. Shehzad, A., Khan, S., and Lee, Y. S. (2012) Curcumin molecular targets in obesity and obesity-related cancers. Future Oncol.* 8, 179–190.
 39. Ghosh, A. K., Kay, N. E., Secreto, C. R., and Shanafelt, T. D. (2009) Curcumin inhibits prosurvival pathways in chronic lymphocytic leukemia B cells and may overcome their stromal protection in combination with EGCG. *Clin. Cancer Res.* 15, 1250–1258.
 40. Yang, C. W., Chang, C. L., Lee, H. C., Chi, C. W., Pan, J. P., et al. (2012) Curcumin induces the apoptosis of human monocytic leukemia THP-1 cells via the activation of JNK/ERK pathways. *BMC Complement. Altern. Med.* 12, 22.
 41. Gao, S. M., Yang, J. J., Chen, C. Q., Chen, J. J., Ye, L. P., et al. (2012) Pure curcumin decreases the expression of WT1 by upregulation of miR-15a and miR-16-1 in leukemic cells. *J. Exp. Clin. Cancer Res.* 31, 27.